Sign in

Gavin Clark-Gardner

Director of Biotechnology Equity Research at Evercore

Gavin Clark-Gartner is a Director of Biotechnology Equity Research at Evercore ISI, specializing in coverage of innovative biotechnology and large-cap pharma companies within the medical sector. He oversees analysis on firms such as Sarepta Therapeutics and seven other NASDAQ- and NYSE-listed biopharmaceutical companies, maintaining a performance record highlighted by a 51.6% success rate and average returns slightly above breakeven on rated stocks. Clark-Gartner began his equity research career after earning a Bachelor of Science degree from Cornell University in 2016, serving as a healthcare analyst at Guidepoint Global and advancing through multiple roles at Evercore since 2020, including Vice President prior to his current directorship. He holds relevant FINRA securities licenses by virtue of his registration as a broker at Evercore Group LLC and has also completed executive education at Columbia Business School.

Gavin Clark-Gardner's questions to Mirum Pharmaceuticals (MIRM) leadership

Question · Q3 2025

Gavin Clark-Gardner asked about Mirum's expectations regarding Paragraph IV filers and the company's confidence in its overall intellectual property portfolio, particularly concerning method patents for LIVMARLI and Volixibat.

Answer

CEO Chris Peetz stated that while the company is within the window to potentially see Paragraph IV filers, it is a routine part of the product lifecycle, and Mirum remains highly confident in its strong IP position, especially for method patents specific to LIVMARLI's dosing in its indications, and is prepared to defend it. No filers have been observed to date.

Ask follow-up questions

Fintool

Fintool can predict Mirum Pharmaceuticals logo MIRM's earnings beat/miss a week before the call

Let Fintool AI Agent track Gavin Clark-Gardner for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free